| abstract |
The present invention comprises a dengue vaccine containing at least one attenuated live dengue virus or attenuated live chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or a sugar alcohol, and optionally an alkali or alkali salt, and an amino acid. And a dengue vaccine containing at least one attenuated live dengue virus or attenuated live chimeric flavivirus, a buffer, at least 150 mg / ml sugar, a carrier, optionally an alkali or alkali salt, and amino acids. Regarding the formulation with. [Selection diagram] Fig. 1 |